Palvella Therapeutics, Inc.
PVLA
$120.57
-$5.22-4.15%
NASDAQ
Corporate Info
Website
Phone Number
484 253 1461
Address
353 W. Lancaster Avenue
Suite 200
Wayne, PA 19087
Suite 200
Wayne, PA 19087
Country
United States
Year Founded
--
Details
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Employees
29
Business Description
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.